Identification of Enhancer RNA CDK6-AS1 as a Potential Novel Prognostic Biomarker in Gastric Cancer

Background: This study aimed to confirm the role of enhancer RNAs (eRNAs) in gastric cancer and their clinical utility.Methods: We used Cox survival and relevance analysis to identify the candidate eRNAs in gastric cancer and performed Gene Ontology and Reactome pathway enrichment to determine the p...

Full description

Bibliographic Details
Main Authors: Shifeng Yang, Xiaoming Zou, Hao Yang, Jiacheng Li, Ange Zhang, Lisha Zhang, Changjian Li, Lei Zhu, Zhen Ma
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-04-01
Series:Frontiers in Genetics
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fgene.2022.854211/full
_version_ 1818150578129207296
author Shifeng Yang
Xiaoming Zou
Hao Yang
Jiacheng Li
Ange Zhang
Lisha Zhang
Changjian Li
Lei Zhu
Zhen Ma
author_facet Shifeng Yang
Xiaoming Zou
Hao Yang
Jiacheng Li
Ange Zhang
Lisha Zhang
Changjian Li
Lei Zhu
Zhen Ma
author_sort Shifeng Yang
collection DOAJ
description Background: This study aimed to confirm the role of enhancer RNAs (eRNAs) in gastric cancer and their clinical utility.Methods: We used Cox survival and relevance analysis to identify the candidate eRNAs in gastric cancer and performed Gene Ontology and Reactome pathway enrichment to determine the potential functions of eRNAs. Correlation between eRNA, tumor-infiltrating immune cells, and drug sensitivity was then analyzed.Results:CDK6-AS1, a long non-coding RNA cyclin-dependent kinase 6, may serve as a poor potential prognostic biomarker candidate in gastric cancer with a positive correlation with its target gene CDK6. The low CDK6-AS1 expression group showed more frequent mutated driver genes than the high expression group. Moreover, CDK6-AS1 is involved in a key oncogenic pathway of the cell cycle and RNA transcription. CDK6-AS1 also shows dysregulations and associations with prognosis at the pan-cancer level. This eRNA may also be associated with immune cell infiltration and drug sensitivity.Conclusion:CDK6-AS1 may be a potential prognostic biomarker and chemotherapeutic drug sensitivity predictor in gastric cancer.
first_indexed 2024-12-11T13:25:09Z
format Article
id doaj.art-dd09a03d060145e19ce0eb0140e0fbdd
institution Directory Open Access Journal
issn 1664-8021
language English
last_indexed 2024-12-11T13:25:09Z
publishDate 2022-04-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Genetics
spelling doaj.art-dd09a03d060145e19ce0eb0140e0fbdd2022-12-22T01:05:37ZengFrontiers Media S.A.Frontiers in Genetics1664-80212022-04-011310.3389/fgene.2022.854211854211Identification of Enhancer RNA CDK6-AS1 as a Potential Novel Prognostic Biomarker in Gastric CancerShifeng YangXiaoming ZouHao YangJiacheng LiAnge ZhangLisha ZhangChangjian LiLei ZhuZhen MaBackground: This study aimed to confirm the role of enhancer RNAs (eRNAs) in gastric cancer and their clinical utility.Methods: We used Cox survival and relevance analysis to identify the candidate eRNAs in gastric cancer and performed Gene Ontology and Reactome pathway enrichment to determine the potential functions of eRNAs. Correlation between eRNA, tumor-infiltrating immune cells, and drug sensitivity was then analyzed.Results:CDK6-AS1, a long non-coding RNA cyclin-dependent kinase 6, may serve as a poor potential prognostic biomarker candidate in gastric cancer with a positive correlation with its target gene CDK6. The low CDK6-AS1 expression group showed more frequent mutated driver genes than the high expression group. Moreover, CDK6-AS1 is involved in a key oncogenic pathway of the cell cycle and RNA transcription. CDK6-AS1 also shows dysregulations and associations with prognosis at the pan-cancer level. This eRNA may also be associated with immune cell infiltration and drug sensitivity.Conclusion:CDK6-AS1 may be a potential prognostic biomarker and chemotherapeutic drug sensitivity predictor in gastric cancer.https://www.frontiersin.org/articles/10.3389/fgene.2022.854211/fullCDK6-AS1CDK6enhancer RNAgastric cancerprognostic biomarker
spellingShingle Shifeng Yang
Xiaoming Zou
Hao Yang
Jiacheng Li
Ange Zhang
Lisha Zhang
Changjian Li
Lei Zhu
Zhen Ma
Identification of Enhancer RNA CDK6-AS1 as a Potential Novel Prognostic Biomarker in Gastric Cancer
Frontiers in Genetics
CDK6-AS1
CDK6
enhancer RNA
gastric cancer
prognostic biomarker
title Identification of Enhancer RNA CDK6-AS1 as a Potential Novel Prognostic Biomarker in Gastric Cancer
title_full Identification of Enhancer RNA CDK6-AS1 as a Potential Novel Prognostic Biomarker in Gastric Cancer
title_fullStr Identification of Enhancer RNA CDK6-AS1 as a Potential Novel Prognostic Biomarker in Gastric Cancer
title_full_unstemmed Identification of Enhancer RNA CDK6-AS1 as a Potential Novel Prognostic Biomarker in Gastric Cancer
title_short Identification of Enhancer RNA CDK6-AS1 as a Potential Novel Prognostic Biomarker in Gastric Cancer
title_sort identification of enhancer rna cdk6 as1 as a potential novel prognostic biomarker in gastric cancer
topic CDK6-AS1
CDK6
enhancer RNA
gastric cancer
prognostic biomarker
url https://www.frontiersin.org/articles/10.3389/fgene.2022.854211/full
work_keys_str_mv AT shifengyang identificationofenhancerrnacdk6as1asapotentialnovelprognosticbiomarkeringastriccancer
AT xiaomingzou identificationofenhancerrnacdk6as1asapotentialnovelprognosticbiomarkeringastriccancer
AT haoyang identificationofenhancerrnacdk6as1asapotentialnovelprognosticbiomarkeringastriccancer
AT jiachengli identificationofenhancerrnacdk6as1asapotentialnovelprognosticbiomarkeringastriccancer
AT angezhang identificationofenhancerrnacdk6as1asapotentialnovelprognosticbiomarkeringastriccancer
AT lishazhang identificationofenhancerrnacdk6as1asapotentialnovelprognosticbiomarkeringastriccancer
AT changjianli identificationofenhancerrnacdk6as1asapotentialnovelprognosticbiomarkeringastriccancer
AT leizhu identificationofenhancerrnacdk6as1asapotentialnovelprognosticbiomarkeringastriccancer
AT zhenma identificationofenhancerrnacdk6as1asapotentialnovelprognosticbiomarkeringastriccancer